<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173627</url>
  </required_header>
  <id_info>
    <org_study_id>9204-06-840</org_study_id>
    <nct_id>NCT01173627</nct_id>
  </id_info>
  <brief_title>Bioequivalence of a Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to Actiq® 400 mcg, Cephalon, Inc.</brief_title>
  <official_title>An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Oral Transmucosal Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Actiq 400 mcg, Cephalon, Inc.) in Normal Human Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the oral bioequivalence of the Mallinckrodt test&#xD;
      fentanyl citrate oral transmucosal 400 mcg troche compared to Actiq 400 mcg (Cephalon, Inc.)&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fentanyl is an opioid analgesic with pharmacological effects similar to morphine. Fentanyl&#xD;
      interacts predominately with the opioid µ-receptor. In clinical settings, fentanyl exerts its&#xD;
      principal pharmacologic effects on the central nervous system. The fentanyl citrate oral&#xD;
      transmucosal troche, Actiq (Cephalon, Inc.), is indicated only for the management of&#xD;
      breakthrough cancer pain in patients with malignancies who are already receiving and who are&#xD;
      tolerant to prior therapy for their underlying persistent cancer pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average bioequivalence is established if the 90% confidence interval on the ratio of formulation averages for AUCt, AUCinf, and Cmax are contained in the interval [80%, 125%].</measure>
    <time_frame>30 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>A - Test fentanyl citrate 400 mcg troche</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test fentanyl citrate 400 mcg troche</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Actiq 400 mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Actiq 400 mcg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test fentanyl citrate 400 mcg troche</intervention_name>
    <description>Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions</description>
    <arm_group_label>A - Test fentanyl citrate 400 mcg troche</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Actiq 400 mcg</intervention_name>
    <description>Actiq 400 mcg administered as a single dose under fasted conditions</description>
    <arm_group_label>B - Actiq 400 mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or non-pregnant, non-lactating females, 18 years of age or older with a minimum&#xD;
             body weight of 120 pounds and a body mass index (BMI) between 19 and 29 inclusive.&#xD;
&#xD;
          -  Female subjects must be postmenopausal for at least one year, surgically sterile, or&#xD;
             using a reliable method of contraception (oral, transdermal, or injectable hormonal&#xD;
             contraceptive; condom with spermicide; IUD; abstinence, etc.) for at least 30 days&#xD;
             prior to and for the duration of study participation.&#xD;
&#xD;
          -  Normal, healthy status confirmed by required screening assessments.&#xD;
&#xD;
          -  Subjects must be able to provide written consent and agree to abide by the study&#xD;
             requirements.&#xD;
&#xD;
          -  Subjects must be able to demonstrate they understand and can perform the dosing&#xD;
             procedure correctly using a placebo troche at check-in to Period 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If female, a positive pregnancy test at any time during the study, pregnant,&#xD;
             lactating, or likely to become pregnant during the study.&#xD;
&#xD;
          -  Female subjects of childbearing potential who have not used adequate forms of birth&#xD;
             control within 30 days of dosing.&#xD;
&#xD;
          -  History of conditions that might contraindicate or require caution be used in the&#xD;
             administration of fentanyl or naltrexone, including: renal impairment, hepatobiliary&#xD;
             or pancreatic disease, gastrointestinal obstruction, cardiac disease, obstructive&#xD;
             pulmonary disease, acute or severe bronchial asthma, hypercarbia, elevated&#xD;
             intracranial pressure, depleted blood volume, paralytic ileus, or hypersensitivity or&#xD;
             idiosyncratic reaction to fentanyl, naltrexone, or any opioids.&#xD;
&#xD;
          -  History of any drug allergy, hypersensitivity, or intolerance which would compromise&#xD;
             the safety of the subject or the study.&#xD;
&#xD;
          -  History of chronic alcohol, drug, or narcotic abuse, chronic use of tranquilizers,&#xD;
             sedatives, aspirin, antibiotics, or other medications.&#xD;
&#xD;
          -  History of malignancy, stroke, or diabetes; cardiac, renal, liver, and pulmonary&#xD;
             disease.&#xD;
&#xD;
          -  History of anxiety, tension, severe agitation, psychiatric disorders, psychosis, or&#xD;
             mental depression requiring hospitalization, psychotherapy, and/or medication.&#xD;
&#xD;
          -  History or diagnosis of epilepsy or other seizure disorder.&#xD;
&#xD;
          -  History of abdominal and/or pelvic surgery within the last 5 years, except elective&#xD;
             surgical sterilization.&#xD;
&#xD;
          -  History of acute abdominal conditions or gastrointestinal disease including, but not&#xD;
             limited to, peptic ulcer, diverticulitis, bowel obstructions, adhesions, ileus,&#xD;
             gastritis, and chronic diarrhea.&#xD;
&#xD;
          -  Subjects presenting with acute illness.&#xD;
&#xD;
          -  Administration of any other investigational drug during the 30 days prior to study&#xD;
             entry.&#xD;
&#xD;
          -  Subjects who have smoked or used nicotine-containing products within 6 months prior to&#xD;
             study entry.&#xD;
&#xD;
          -  Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma&#xD;
             within 14 days prior to study entry, including that withdrawn during the conduct of&#xD;
             any other clinical study.&#xD;
&#xD;
          -  Positive test results for HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
          -  Positive test results for drugs of abuse or alcohol.&#xD;
&#xD;
          -  Subjects who have taken prescription drugs, except hormonal contraception, within 14&#xD;
             days or over-the-counter medications (including herbal preparations) within 7 days&#xD;
             prior to study drug administration except for standard daily dose multivitamins, which&#xD;
             are excluded after check-in to Period 2.&#xD;
&#xD;
          -  Any subject experiencing adverse events to the -13 and/or -1 hour doses of naltrexone,&#xD;
             that in the investigator's opinion, are indicative of possible previous opioid&#xD;
             use/abuse, or that would prevent tolerance of additional doses of naltrexone, will be&#xD;
             withdrawn from the study prior to dosing with fentanyl.&#xD;
&#xD;
          -  Subjects with dental braces or partial dentures.&#xD;
&#xD;
          -  Subjects presenting with a history of gum disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Neuman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>July 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2010</study_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <name_title>Herbert Neuman, MD/Chief Medical Officer</name_title>
    <organization>Mallinckrodt</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Fentanyl</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

